Page last updated: 2024-08-17

quinoxalines and carbamates

quinoxalines has been researched along with carbamates in 225 studies

Research

Studies (225)

TimeframeStudies, this research(%)All Research%
pre-19909 (4.00)18.7374
1990's1 (0.44)18.2507
2000's2 (0.89)29.6817
2010's147 (65.33)24.3611
2020's66 (29.33)2.80

Authors

AuthorsStudies
Ferrando, R; Raynaud, JP; Spanoghe, JP; Truhaut, R1
Brun, GL; Mallet, V; Surette, D1
Curley, JE; Gonci, DA; Goras, JT; Gordon, PN; Murai, K1
Babcock, WE; Chalquest, RR; Rainier, RH; Thrasher, GW2
Holder, JM; Sinclair, AN1
Burrell, RA; Cox, JM; Savins, EG1
Harrington, R; Hooper, BE; Troutt, HF1
Raynaud, JP1
Carter, DB; Im, WB; Sethy, VH; Tang, AH; TenBrink, RE1
Barnes, NY; Parent, AT; Sisodia, SS; Taniguchi, Y; Thinakaran, G1
Kovacs, FE; Szabo, B; Urbanski, MJ1
Lilja, AM; Marutle, A; Nordberg, A; Porras, O; Storelli, E1
Baudot, R; Cren-Olivé, C; Feidt, C; Fratta, C; Lazartigues, A; Thomas, M; Wiest, L1
Burlein, C; Carroll, SS; Claudio, G; Coleman, PJ; Di Filippo, M; Dimuzio, JM; Fandozzi, C; Ferrara, M; Gates, AT; Graham, DJ; Harper, S; Hazuda, DJ; Huang, Q; Liverton, NJ; Ludmerer, SW; McCauley, JA; McHale, C; Monteagudo, E; Olsen, DB; Pucci, V; Rowley, M; Rudd, MT; Soriano, A; Stahlhut, MW; Summa, V; Vacca, JP1
Ban, Y; Liu, H; Xue, W; Yao, X1
Beutner, G; Dreher, SD; Humphrey, G; Kim, M; Kuethe, J; Linn, K; Marcune, B; Pei, T; Yasuda, N; Zhong, YL1
Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I; Zappulo, E1
Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J1
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E1
Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D1
Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E1
Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J1
Cornberg, M; Manns, MP1
Barr, E; Buti, M; Calleja, JL; DiNubile, MJ; Forns, X; Gilbert, C; Gordon, SC; Hofer, H; Howe, AY; Lawitz, E; Palcza, J; Robertson, MN; Wahl, J; Zuckerman, E2
Barr, E; Ben Ari, Z; Brown, DD; Butterton, JR; DiNubile, MJ; Ghalib, R; Nguyen, BY; Pockros, PJ; Reddy, KR; Robertson, MN; Wahl, J; Wan, S; Zeuzem, S; Zhao, Y1
Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H1
Brown, A; Gendrano, IN; Howe, A; Hwang, P; Lagging, M; Mantry, PS; Mobashery, N; Ramji, A; Robertson, M; Vierling, JM; Wahl, J; Weilert, F; Zhang, B1
Bukh, J; Gottwein, JM; Humes, DG; Jensen, SB; Li, YP; Ramirez, S; Serre, SB1
Barr, E; Bloch, M; Gress, J; Katlama, C; Klopfer, S; Lalezari, J; Mallolas, J; Matthews, GV; Nelson, M; Nguyen, BY; Orkin, C; Platt, HL; Robertson, MN; Rockstroh, JK; Saag, MS; Shaughnessy, M; Sulkowski, M; Wahl, J; Zamor, PJ1
Barr, E; Bruchfeld, A; Greaves, W; Hassanein, T; Jackson, B; Liapakis, A; Londoño, MC; Martin, P; Monsour, H; Nelson, DR; Nguyen, BY; Pol, S; Robertson, M; Roth, D; Silva, M; Wahl, J; Wan, S; Zamor, PJ; Zuckerman, E1
Hubbard, H; Lawitz, E; Vizuete, J1
Ali, A; Aydin, C; Kurt Yilmaz, N; Prachanronarong, KL; Schiffer, CA; Soumana, DI1
Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D1
Nelson, DR; Peter, J1
Gordon, SC; Jafri, SM; Sulejmani, N1
Cope, R; Friedman, ML; Sorbera, MA1
Asante-Appiah, E; Black, T; Bystol, K; Chase, R; Curry, S; Hazuda, D; Howe, AY; Ingravallo, P; Lahser, FC; Liu, R; McMonagle, P; Xia, E1
Alric, L; Bonnet, D1
Borgia, G; Buonomo, AR; Gentile, I; Pinchera, B; Scotto, R; Zappulo, E1
Keating, GM1
Park, SH1
Warparkowski, A1
Zimmermann, W1
Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y1
Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E1
Saab, S; Suraweera, D; Weeratunga, AN1
Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC1
Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z1
Andreone, P; Gamal, N1
Bagchi, S; Kottilil, S; Papudesu, C1
Alric, L; Kamar, N; Rostaing, L1
Barr, E; Black, S; Buti, M; Dutko, FJ; Gane, EJ; Gress, J; Haber, B; Kwo, P; Lin, L; Lupinacci, L; Pearlman, B; Peng, CY; Robertson, M; Serfaty, L; Shafran, S; Stryszak, P; Vierling, JM; Wahl, J1
Barr, E; Dutko, FJ; Evans, B; Gutierrez, JA; Haber, B; Howe, A; Huang, HC; Hwang, P; Landaverde, CE; Lawitz, E; Li, JJ; Poordad, F; Robertson, M; Wahl, J; Wells, JT1
Black, S; Caro, L; Chayama, K; Fujimoto, G; Itoh, Y; Iwasa, T; Karino, Y; Kawada, N; Kumada, H; Mochida, S; Okanoue, T; Robertson, MN; Suzuki, Y; Takaki, S; Toyoda, H; Wahl, J; Yatsuzuka, N; Yodoya, E; Yoshiji, H1
Elbasha, EH; Nwankwo, C; Robertson, MN1
Elbasha, E; Greaves, W; Nwankwo, C; Roth, D1
Chen, H; Huang, P; Li, J; Liu, M; Wang, J; Yao, Y; Yu, R; Yue, M; Zang, F; Zhang, Y1
Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J1
Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y1
Lim, SG1
Asante-Appiah, E; Black, S; Chase, R; Curry, S; Guo, Z; Hu, Y; Ingravallo, P; McMonagle, P1
Butterton, JR; Caro, L; Feng, HP; Guo, Z; Huang, X; Ma, J; Mangin, E; Marshall, WL; O'Reilly, TE; Panebianco, D; Talaty, J; Yeh, WW1
Barr, E; Ben-Ari, Z; Bourlière, M; Chase, R; Colombo, M; Haber, B; Hézode, C; Hwang, P; Lee, WM; Marco, VD; Morgan, L; Nguyen, BY; Qiu, J; Robertson, M; Spengler, U; Strasser, SI; Talwani, R; Wahl, J1
Alston, S; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Reau, N; Reddy, KR; Reeve, B; Sarkar, S; Sterling, RK; Stewart, P1
Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y1
Asante-Appiah, E; Barr, E; Gane, E; Haber, B; Hwang, P; Luketic, V; Nahass, R; Robertson, M; Wahl, J1
Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J1
Arduino, JM; Barr, E; Bruchfeld, A; Greaves, W; Hwang, P; Londoño, MC; Martin, P; Monsour, H; Nelson, DR; Nguyen, BY; Pol, S; Robertson, M; Roth, D; Silva, M; Wahl, J1
Hussar, DA2
Cheng, PN; Chiu, YC; Sun, HY; Tsai, WJ; Tseng, CY; Young, KC1
Jacobson, IM; Voaklander, R1
Asante-Appiah, E; Iwasa, T; Kinoshita, K; Nakamura, K1
Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V1
Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM1
Agarwal, K; Barr, E; Ben-Ari, Z; Butterton, JR; Chen, HL; Dutko, FJ; Esteban, R; Fernsler, D; Fitzgerald, B; Foster, GR; Gane, EJ; Gao, W; Gerstoft, J; Grandhi, A; Huang, HC; Laursen, AL; Li, JJ; Liu, H; Nguyen, BT; Pianko, S; Plank, RM; Roberts, SK; Robertson, MN; Su, FH; Thompson, AJ; Wahl, J; Wan, S; Yeh, WW; Zeng, Z; Zeuzem, S; Zuckerman, E1
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Olemy, A1
Arends, JE; Brinkman, K; Burger, DM; Dofferiiof, ASM; Reiss, P; Rijnders, B; Smit, C; Smolders, EJ; T M M de Kanter, C; van der Valk, M1
Angus, P; Butterton, JR; Caro, L; Fandozzi, C; Fraser, IP; Gane, E; Guo, Z; Ho, M; Iwamoto, M; Marbury, T; Panebianco, D; Reitmann, C; Smith, WB; Talaty, J; Uemura, N; Wenning, L; Yeh, WW1
Alves, K; Atarashi, T; Burroughs, M; Chayama, K; Eguchi, Y; Karino, Y; Kato, K; Kawakami, Y; Krishnan, P; Kumada, H; Naganuma, A; Oberoi, RK; Pilot-Matias, TJ; Pugatch, DL; Redman, R; Sato, K; Seike, M; Suzuki, F; Takei, Y; Watanabe, T; Xie, W; Yoshiji, H1
Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K1
Aschenbrenner, DS1
Alric, L; Bellissant, E; Bourlière, M; de Lédinghen, V; Gibowski, S; Hézode, C; Jézéquel, C; Laforest, C; Larrey, D; Métivier, S; Pailhé, A; Pawlotsky, JM; Pol, S; Renault, A; Samuel, D; Tran, A; Tual, C; Zoulim, F1
Kottilil, S; O'Brien, TR; Pfeiffer, RM1
Chahine, EB; Childs-Kean, LM; Kelley, D1
Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E1
Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S1
Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM1
Besandre, R; Liu, HW1
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Garrett, G; Huang, X; Iwamoto, M; Lasseter, KC; Liu, F; Marbury, T; Marshall, WL; Panebianco, D; Preston, RA; Wenning, L; Yeh, WW1
Younossi, ZM1
Danta, M; Sanagapalli, S1
Barr, E; Cheng, W; George, J; Hwang, P; Kumada, H; Platt, H; Robertson, M; Serfaty, L; Sperl, J; Strasser, S; Talwani, R; Vierling, J; Wahl, J; Zeuzem, S1
Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S1
Asante-Appiah, E; Asselah, T; Barr, E; de Ledinghen, V; Gerstoft, J; Hwang, P; Nguyen, BY; Pockros, PJ; Reesink, H; Robertson, M; Serfaty, L; Talwani, R; Wahl, J1
Bair, N; Bowring, MG; Brown, DM; Chattergoon, MA; Desai, NM; Durand, CM; Massaccesi, G; Naqvi, FF; Ostrander, D; Reyad, A; Segev, DL; Sugarman, J; Sulkowski, M; Wesson, R1
Abergel, A; Clément, A; Di Martino, V; Durand-Zaleski, I; Levy-Bachelot, L; Maunoury, F; Nwankwo, C; Thervet, E1
Deeks, ED; Heo, YA1
Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y1
Cheung, TT; Feng, HP; Li, W; Ling Lam, KS; Mu, S; Wang, J; Wang, Z; Yan Chiu, JW; Yeh, WW; Yuen, MF; Yung Cheung, BM; Zhao, XM1
Abe, H; Asano, T; Atsukawa, M; Deguchi, A; Fujioka, S; Hiraoka, A; Iio, E; Ishikawa, T; Itobayashi, E; Iwakiri, K; Kato, K; Kondo, C; Kumada, T; Masaki, T; Michitaka, K; Mikami, S; Moriya, A; Ogawa, C; Okubo, H; Okubo, T; Senoh, T; Shimada, N; Tada, T; Takaguchi, K; Tamai, H; Tanaka, Y; Tani, J; Toyoda, H; Tsubota, A; Tsuji, K; Uojima, H; Watanabe, T; Yoneyama, H1
Caroleo, B; Colangelo, L; De Sarro, G; Gallelli, L; Perticone, M1
Abdelazim, AH; Attia, KAM; El-Abasawi, NM; El-Dosoky, M; El-Olemy, A1
Cao, Y; El-Serag, HB; Erickson, KF; Kanwal, F; Kramer, JR; Puenpatom, A; Smith, D1
Waked, I1
Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J1
Summers, BB1
Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM1
Attar, BM; Gandhi, S; Jaiswal, P; Szynkarek, R; Ton, L; Yap, JE1
Bloom, RD; Potluri, VS1
Flamm, SL1
Occhipinti, V; Rumi, MG1
Arrais de Castro, R; Borges-Costa, J; Tato Marinho, R; Vilas, P1
Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S1
Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M1
Sulkowski, MS1
Ali, A; Huang, W; KurtYilmaz, N; Leidner, F; Matthew, AN; Newton, A; Petropoulos, CJ; Schiffer, CA1
Agrawal, S; Asante-Appiah, E; Black, S; Bystol, K; Carr, D; Chase, R; Curry, S; Ferrari, E; Ingravallo, P; Kozlowski, J; Lahser, F; Liu, R; McMonagle, P; Rokosz, L; Tong, L; Yu, W1
Chen, P; Liu, Q; Ma, A1
Kottilil, S; Mathur, P; Wilson, E1
Morikawa, K; Nakamura, A; Sakamoto, N; Shimazaki, T1
Hinds, AE; Pearlman, BL1
Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Ooho, A; Satoh, T; Shimoda, S; Takahashi, K1
Devine, P; Kim, J; Waldman, J; Wang, T; Xu, F1
Altice, FL; Barr, E; Haber, B; Hwang, P; Jacobson, I; Robertson, M; Rockstroh, J; Serfaty, L1
Bondin, M; Cacoub, P; Fabrizi, F; Negro, F1
Cenderello, G; Di Biagio, A; Taramasso, L1
Butterton, JR; Caro, L; Fandozzi, C; Feng, HP; Fraser, I; Guo, Z; Huang, X; Iwamoto, M; Jumes, P; Ma, J; Mangin, E; Marshall, WL; Panebianco, D; Ross, LL; Talaty, J; Yeh, WW1
Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M1
Ammerlaan, HSM; Arends, JE; Bierman, WF; Boerekamps, A; Claassen, MAA; De Weggheleire, A; den Hollander, J; Dofferhoff, ASM; Florence, E; Hullegie, SJ; Kootstra, GJ; Lauw, FN; Leyten, EM; Popping, S; Posthouwer, D; Rijnders, BJA; Schinkel, J; Soetekouw, R; van de Vijver, DACM; van den Berk, GE; van Kasteren, ME1
Martinello, M; Matthews, GV1
Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T1
Botejue, A; Devine, PN; Forte, J; Huffman, MA; Kassim, AM; Kim, T; McIntosh, JA; Rozzell, D; Zhang, C1
Bhagunde, P; Butterton, JR; Caro, L; Du, L; Fandozzi, C; Feng, HP; Guo, Z; Iwamoto, M; Marshall, WL; Panebianco, D; Wenning, L; Yeh, WW1
Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV1
Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW1
Abt, PL; Acker, M; Atluri, P; Bar, KJ; Bermudez, C; Bloom, RD; Blumberg, EA; Gentile, C; Goldberg, DS; Goldberg, LR; Hasz, R; Hornsby, N; Levine, MH; McLean, RC; Porrett, P; Reddy, KR; Reese, PP; Sicilia, A; Smith, J; Suplee, L; Van Deerlin, VM; Woodards, A; Zahid, MN1
Ankrom, W; Fan, L; Iwamoto, M; Khalilieh, S; Mitra, P; Sanchez, RI; Sterling, LM; Stoch, SA; Triantafyllou, I; Wolford, D; Yee, KL1
Bhanja, S; Caro, L; Charles, ED; Everson, GT; Firpi-Morell, R; Hwang, P; Jacobson, IM; Platt, H; Poordad, F; Robertson, M; Verna, EC1
Bukh, J; Dietz, J; Fahnøe, U; Filskov, J; Fourati, S; Ghanem, L; Gottwein, JM; Humes, D; Jensen, SB; Krarup, H; Pawlotsky, JM; Pedersen, MS; Pham, LV; Pihl, AF; Ramirez, S; Sarrazin, C; Schønning, K; Serre, SBN; Sølund, CS; Tang, Q; Weis, N1
Pawlotsky, JM1
Aghemo, A; Parigi, TL; Torres, MCP1
Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M1
Hinds, A; Pearlman, B; Perrys, M1
Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW1
Colace, T; Dewitt, K; Hermans, A; Kesisoglou, F; Marota, M; Xu, W1
Chung, WJ; Haber, B; Heo, J; Hwang, P; Kim, DY; Kim, YJ; Kulasingam, S; Lee, YJ; Paik, SW; Sim, E; Tak, WY; Talwani, R1
Appleby, T; Barauskas, O; Chan, K; Cheng, G; Jin, D; Karki, KK; Katana, A; Kato, D; Kobayashi, T; Link, JO; Martinez, R; Ramey, K; Sangi, M; Schrier, A; Schultz, BE; Siegel, D; Taylor, JG; Tran, CV; Villaseñor, AG; Vivian, R; Wang, K; Wang, Y; Yang, CY; Yang, ZY; Zablocki, J; Zipfel, S1
Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E1
Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ1
Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J1
Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A1
Antón, JJ; Arenas, JI; Bernal, E; Casado, M; Chueca, N; Collado, A; De la Iglesia, A; Espinosa, MD; García, F; García-Bujalance, S; García-Deltoro, M; García-Herola, A; Hernández-Quero, J; Hidalgo-Tenorio, C; Lozano, AB; Macías, J; Martínez, O; Omar, M; Pascasio, JM; Pérez, AB; Pineda, JA; Rincón, P; Ríos, MJ; Rivero-Juárez, A; Rosales, JM; Salmerón, J; Santos, J; Selfa, A; Téllez, F; Vélez, M; Von-Wichmann, MÁ1
Alcantarini, C; Angelini Zucchetti, T; Bargiacchi, O; De Carlis, L; Ferla, F; Lauterio, A; Merli, M; Puoti, M; Rossotti, R; Travi, G1
Cariti, G; Di Perri, G1
Cheng, PN; Liu, CJ; Lo, CC; Tseng, IH; Tseng, KC1
Chen, J; Chen, L; Lu, M; Stämpfli, A1
Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Blaszkowska, M; Buczyńska, I; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D1
Ahmed, SNS; Alric, L; Asante-Appiah, E; Asselah, T; Bronowicki, JP; Brown, D; Guidoum, A; Haber, BA; Hagen, K; Hall, JD; Hanna, GJ; Hezode, C; Hwang, P; Larrey, D; Leroy, V; Loustaud-Ratti, V; Nguyen-Khac, E; Ozenne, V; Pol, S; Robertson, MN; Serfaty, L; Su, FH; Talwani, R; Tran, A1
Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawaoka, T; Morio, K; Murakami, E; Nakahara, T; Ohya, K; Tsuge, M; Yamauchi, M1
Bukh, J; Fernandez-Antunez, C; Li, YP; Mikkelsen, LS; Pedersen, J; Ramirez, S1
Deshayes, E; Fersing, C; Guiu, B; Meunier, L; Quenet, F1
Choi, DT; El-Serag, HB; Erickson, KF; Kanwal, F; Kramer, JR; Puenpatom, A; Yu, X1
Ali, A; Henes, M; Hou, S; Kosovrasti, K; Kurt Yilmaz, N; Leidner, F; Schiffer, CA; Timm, J1
Al-Ahmed, SH; Aldrazi, FA; Alfouzan, WA; Alsuliman, SA; Bazzi, AM; Haque, S; Rabaan, AA1
Chung, RT; Holmes, JA1
Guyader, D; Jézéquel, C; Lalanne, S; Lemaitre, F; Mercerolle, M; Pronier, C; Tron, C; Verdier, MC1
Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX1
Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P1
Chen, J; Lei, P; Li, G; Li, Y1
Boyd, A; Chas, J; Chevaliez, S; Girard, PM; Lacombe, K; Miailhes, P; Peytavin, G; Pialoux, G; Piroth, L; Rosenthal, E; Rougier, H; Valantin, MA; Yazdanpanah, Y1
Cornberg, M; Guenther, V; Heyne, R; Hinrichsen, H; John, C; Klinker, H; Martin, K; Simon, KG; Stoehr, A; Witte, V; Zeuzem, S1
Barash, D; Chayama, K; Churkin, A; Cotler, SJ; Dahari, H; Dasgupta, S; Etzion, O; Gorstein, E; Imamura, M; Nakahara, T; Tsuge, M; Uprichard, SL; Yardeni, D1
Abergel, A; Andant, N; Asselah, T; Bailly, F; Buchard, B; Chanteranne, B; Di Martino, V; Dodel, M; Faure, F; Fouchard-Hubert, I; Gournay, J; Lamblin, G; Larrey, D; Loustaud-Ratti, V; Mallat, A; Muti, L; Pereira, B; Pol, S; Reymond, M; Samuel, D; Teilhet, C; Tran, A1
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C1
Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ1
Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B1
Abbink, EJ; Burger, DM; Colbers, A; Drenth, JPH; Pijnenburg, DWM; van Seyen, M1
Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH1
Brown, DD; Haber, BA; Klopfer, SO; Kwo, P; Nangia, G; Reddy, KR; Robertson, MN; Vierling, JM1
Claar, E; Coppola, N; De Pascalis, S; Fraia, AD; Messina, V; Minichini, C; Occhiello, L; Pisaturo, M; Sangiovanni, V; Starace, M1
Bhowmik, D; Jagadeesan, R; Kumar, D; Kumar, N; Nandi, R; Prakash, A1
Ali, HN; Farooq, S; Iftikhar, H; Naveed, H; Shahzad-Ul-Hussan, S1
Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM1
Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kobara, H; Masaki, T; Mimura, S; Morishita, A; Nakahara, M; Nomura, T; Oryu, M; Oura, K; Sakamoto, T; Shimotohno, K; Tadokoro, T; Takuma, K; Tani, J; Tsutsui, K; Wakita, T; Yoneyama, H1
Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A1
Avihingsanon, A; Chayanupatkul, M; Chittmittraprap, S; Chuaypen, N; Pratedrat, P; Tangkijvanich, P1
Chen, YC; Cheng, YT; Chien, RN; Hsieh, YC; Jeng, WJ; Lin, CY; Liu, YC; Sheen, IS; Teng, W1
Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S1
Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S1
Chen, SC; Cheng, TS; Chuang, WL; Dai, CY; Hsieh, PH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML1
Abdel-Kareem, RF; Abdelazim, AH; Attia, KAM; El-Olemy, A; Hasan, MA; Ramzy, S1
Chen, H; Li, C; Liang, J; Tian, J; Xiang, H1
Butterton, JR; Caro, L; Fandozzi, CM; Feng, HP; Fraser, IP; Guo, Z; Iwamoto, M; Levine, V; Panebianco, D; Prueksaritanont, T; Swearingen, D; Wolford, D; Yeh, WW1
Abdelazim, AH; Shahin, M; Zeid, AM1
Buonomo, AR; Cattaneo, L; Coppola, C; Coppola, N; De Pascalis, S; Gentile, I; Martini, S; Mercinelli, S; Messina, V; Nerilli, M; Pinchera, B; Scotto, R; Staiano, L; Stanzione, M; Stornaiuolo, G1
Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A1
Sarrazin, C1
Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D1
Campo-Moneo, E; de Los Santos, I; García, F; García-Fraile, L; González-Serna, A; Granados, R; Macías, J; Merino, D; Morano, LE; Pineda, JA; Real, LM; Téllez, F; Vera-Mendez, F1
Behera, SK; Contractor, D; Jain, A; Kalia, K; Kumar, D; Shard, A; Vhora, N1
Hidaka, I; Hirao, T; Ishida, H; Sakaida, I; Suenaga, R; Suka, M1
Ciangherotti, CE; Orozco, CA; Suarez-Torres, JD1
Brotherton, AL; Garrett, KL; Noska, AJ; Shah, RB1
Abidi, SH; Ali, S; Allemailem, KS; Almansour, NM; Amerzhanov, D; Ibrahim, MAA; la Fleur, P; Lukac, M; Rafaqat, W1
Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S1
Begum, F; Ray, U; Srivastava, AK1
Abdouljoud, M; Agopian, VG; Akoad, ME; Anderson, MP; Anderson, MS; Aucejo, F; Cameron, A; Cannon, RM; Chapman, WC; Chavarriaga, A; Delman, AM; Dhanireddy, K; Doyle, M; Emamaullee, J; Esquivel, CO; Feizpour, CA; Foley, DP; Ganesh, SR; Humar, A; Kazimi, MM; Kim, A; Kim, SC; Kubal, CA; Locke, JE; Magliocca, JF; Maithel, SK; Moris, D; Moro, A; Nguyen, MH; Olyaei, A; Orloff, SL; Salgia, RJ; Shah, SA; Simpson, MA; Sonnenday, CJ; Subramanian, V; Sudan, DL; Tran, BV; Turgeon, MK; Vagefi, PA; Wedd, JP; Wongjirad, CP1
Chang, WC; Chen, HW; Hsieh, TY; Lin, JC1
Flamm, SL; Martin, MT; Patel, S1
Calvaruso, V; Ceccherini-Silberstein, F; Craxì, A; Di Maio, VC; Di Marco, V; Ferraro, D; Gibilaro, G; La Mantia, C; Licata, A; Petta, S; Reina, G1
Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H1
Chen, CH; Cheng, SB; Jeng, LB; Lai, PC; Lee, TY; Tsai, SF; Wu, MJ; Yang, SS; Yu, TM1
Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L1
Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F1
Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD1
Guo, M; Ke, L; Liu, J; You, R1
Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW1
Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ1
Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS1
Butt, ZA1

Reviews

38 review(s) available for quinoxalines and carbamates

ArticleYear
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
    Expert opinion on investigational drugs, 2014, Volume: 23, Issue:5

    Topics: Amides; Animals; Carbamates; Clinical Trials as Topic; Cyclopropanes; Hepatitis C; Humans; Protease Inhibitors; Quinoxalines; Sulfonamides; Treatment Outcome

2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
    Expert review of anti-infective therapy, 2014, Volume: 12, Issue:7

    Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine

2014
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
    Clinics in liver disease, 2015, Volume: 19, Issue:4

    Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins

2015
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins

2016
Hepatitis C virus: how to provide the best treatment with what I have.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36 Suppl 1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Young Adult

2016
Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
    Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:3

    Topics: Administration, Oral; Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2016
New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
    Journal of pharmacy practice, 2017, Volume: 30, Issue:3

    Topics: Amides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Quinoxalines; Renal Insufficiency; Sulfonamides; Treatment Outcome

2017
Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Protease Inhibitors; Quinoxalines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sulfonamides

2016
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
    Expert opinion on investigational drugs, 2016, Volume: 25, Issue:5

    Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigational; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Quinoxalines; Sofosbuvir; Sulfonamides

2016
Elbasvir/grazoprevir (Zepatier) for hepatitis C.
    The Medical letter on drugs and therapeutics, 2016, Feb-29, Volume: 58, Issue:1489

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Fatigue; Hepatitis C; Humans; Imidazoles; Nausea; Quinoxalines; Sulfonamides

2016
Elbasvir/Grazoprevir: First Global Approval.
    Drugs, 2016, Volume: 76, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Protease Inhibitors; Quinoxalines; Sulfonamides

2016
[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Volume: 67, Issue:3

    Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Practice Guidelines as Topic; Quinoxalines; Republic of Korea; Sofosbuvir; Sulfonamides

2016
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides

2016
Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
    Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:7

    Topics: Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides

2016
Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.
    Hepatology international, 2017, Volume: 11, Issue:2

    Topics: Amides; Animals; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2017
Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.
    Transplant international : official journal of the European Society for Organ Transplantation, 2016, Volume: 29, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Polyethylene Glycols; Quinoxalines; Ribavirin; Sulfonamides; Transplant Recipients

2016
HCV management in resource-constrained countries.
    Hepatology international, 2017, Volume: 11, Issue:3

    Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine

2017
NewDrugs 2017, part 2.
    Nursing, 2017, Volume: 47, Issue:7

    Topics: Amides; Antibodies, Monoclonal, Humanized; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Therapy; gamma-Cyclodextrins; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Peptides; Phenylalanine; Quinoxalines; Sofosbuvir; Sugammadex; Sulfonamides; Sulfones; Thioglycolates; Triazoles; United States; United States Food and Drug Administration

2017
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
    Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2017
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:9

    Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome

2017
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
    The Annals of pharmacotherapy, 2018, Volume: 52, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2018
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
    Drugs, 2018, Volume: 78, Issue:5

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins

2018
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
    Drugs of today (Barcelona, Spain : 1998), 2018, Volume: 54, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome

2018
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
    Antiviral therapy, 2019, Volume: 24, Issue:1

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2019
Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence.
    Drug design, development and therapy, 2018, Volume: 12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Molecular Conformation; Quinoxalines; Sulfonamides

2018
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
    Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides

2018
Expert opinion on the management of renal manifestations of chronic HCV infection.
    Antiviral therapy, 2018, Volume: 23, Issue:Suppl 2

    Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Disease Management; Drug Therapy, Combination; Expert Testimony; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Practice Guidelines as Topic; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Sulfonamides; Uracil; Valine

2018
Treatment of hepatitis C virus genotype 4 in the DAA era.
    Virology journal, 2018, 11-22, Volume: 15, Issue:1

    Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine

2018
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Hepatology (Baltimore, Md.), 2019, Volume: 70, Issue:3

    Topics: 2-Naphthylamine; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Denmark; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Prognosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Uracil; Valine

2019
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
    Seminars in liver disease, 2019, Volume: 39, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
    Clinical and molecular hepatology, 2019, Volume: 25, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2019
Overview of hepatitis C infection, molecular biology, and new treatment.
    Journal of infection and public health, 2020, Volume: 13, Issue:5

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2020
New approaches in viraemic organ transplantation and antiviral therapies.
    Nature reviews. Gastroenterology & hepatology, 2020, Volume: 17, Issue:2

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants

2020
Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Safety; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2020
Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
    Journal of viral hepatitis, 2020, Volume: 27, Issue:11

    Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2020
Treatment failure with DAA therapy: Importance of resistance.
    Journal of hepatology, 2021, Volume: 74, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Macrocyclic Compounds; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2021
Elbasvir/grazoprevir administered for 12 weeks via percutaneous endoscopic gastrostomy tube achieves sustained virologic response: A case report and a review of the literature.
    Pharmacotherapy, 2021, Volume: 41, Issue:7

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Gastrostomy; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
    Frontiers in public health, 2022, Volume: 10

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides

2022

Trials

57 trial(s) available for quinoxalines and carbamates

ArticleYear
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
    Gastroenterology, 2014, Volume: 147, Issue:2

    Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Young Adult

2014
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12

    Topics: Amides; Carbamates; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepatitis C; Humans; Interferons; Quinoxalines; Ribavirin; Sulfonamides

2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2015
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load; Young Adult

2015
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
    Annals of internal medicine, 2015, Jul-07, Volume: 163, Issue:1

    Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Nausea; Quinoxalines; Sulfonamides; Treatment Outcome; Viral Load; Young Adult

2015
Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:2

    Topics: Adult; Aged; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins; Young Adult

2016
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Jan-01, Volume: 62, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Ribavirin; Salvage Therapy; Sulfonamides; Treatment Outcome

2016
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
    The lancet. HIV, 2015, Volume: 2, Issue:8

    Topics: Adult; Amides; Antiviral Agents; Australia; Benzofurans; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; RNA, Viral; Sulfonamides; Treatment Outcome; United States; Viral Load

2015
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
    Lancet (London, England), 2015, Oct-17, Volume: 386, Issue:10003

    Topics: Aged; Amides; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Renal Insufficiency, Chronic; RNA, Viral; Sulfonamides; Treatment Outcome

2015
[High chance of healing for opiate dependent patients].
    MMW Fortschritte der Medizin, 2016, Mar-03, Volume: 158, Issue:4

    Topics: Amides; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Medication Adherence; Opiate Substitution Treatment; Opioid-Related Disorders; Quinoxalines; Substance Abuse, Intravenous; Sulfonamides

2016
[New therapy option in the pipeline].
    MMW Fortschritte der Medizin, 2016, May-12, Volume: 158, Issue:9

    Topics: Administration, Oral; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2016
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gastroenterology, 2016, Volume: 151, Issue:3

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult

2016
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
    Journal of viral hepatitis, 2016, Volume: 23, Issue:10

    Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
    Gastroenterology, 2016, Volume: 151, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Gastroenterology, 2016, Volume: 151, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult

2016
Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection.
    Gastroenterology, 2017, Volume: 152, Issue:1

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Young Adult

2017
Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:2

    Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Viral Load

2017
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    Journal of gastroenterology, 2017, Volume: 52, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2017
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
    Hepatology (Baltimore, Md.), 2017, Volume: 65, Issue:6

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult

2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:3

    Topics: Administration, Oral; Adult; Amides; Benzofurans; Biopsy, Needle; Blood Coagulation Disorders, Inherited; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunohistochemistry; Liver Function Tests; Male; Middle Aged; Quinoxalines; Reference Values; Severity of Illness Index; Sulfonamides; Treatment Outcome

2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology, 2017, Volume: 153, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult

2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    The New England journal of medicine, 2017, 06-01, Volume: 376, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins

2017
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:8

    Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Quinoxalines; Renal Insufficiency, Chronic; Sulfonamides; Sustained Virologic Response

2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2,
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:11

    Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine

2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST
    The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:11

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Thiazoles; Uridine; Young Adult

2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12

    Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Male; Middle Aged; Protease Inhibitors; Quinoxalines; Sulfonamides; Young Adult

2017
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    Journal of gastroenterology, 2018, Volume: 53, Issue:4

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins

2018
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 03-19, Volume: 66, Issue:7

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Retreatment; Ribavirin; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure

2018
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
    Gastroenterology, 2017, Volume: 153, Issue:6

    Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interleukins; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2017
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
    The New England journal of medicine, 2018, 01-25, Volume: 378, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load

2018
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:9

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Internationality; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Young Adult

2018
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.
    Annals of internal medicine, 2018, 04-17, Volume: 168, Issue:8

    Topics: Adolescent; Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Graft Rejection; Graft Survival; Hepatitis C; Humans; Imidazoles; Kidney; Kidney Transplantation; Male; Middle Aged; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Tissue Donors; Treatment Outcome

2018
A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
    Clinical therapeutics, 2018, Volume: 40, Issue:5

    Topics: Adult; Amides; Antiviral Agents; Asian People; Benzofurans; Carbamates; Cyclopropanes; Female; Humans; Imidazoles; Male; Quinoxalines; Sulfonamides; Young Adult

2018
Efficacy and Safety of Elbasvir-Grazoprevir Fixed Dose in the Management of Polytreated HCV Patients: Evidence From Real-Life Clinical Practice.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Sulfonamides

2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:8

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins

2018
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:1

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Journal of hepatology, 2018, Volume: 69, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins

2018
The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:3

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Data Interpretation, Statistical; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Predictive Value of Tests; Quinoxalines; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sustained Virologic Response; Viral Load

2019
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
    The Journal of antimicrobial chemotherapy, 2019, 03-01, Volume: 74, Issue:3

    Topics: Adult; Amides; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzofurans; Carbamates; Chromatography, Liquid; Coinfection; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Imidazoles; Male; Mass Spectrometry; Middle Aged; Oxazines; Piperazines; Pyridones; Quinoxalines; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Young Adult

2019
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.
    The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:4

    Topics: Acute Disease; Administration, Oral; Adult; Amides; Antiviral Agents; Belgium; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Male; Middle Aged; Netherlands; Quinoxalines; Sexually Transmitted Diseases; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Failure; Treatment Outcome

2019
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
    Journal of viral hepatitis, 2019, Volume: 26, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:5

    Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Quinoxalines; Renal Dialysis; Sulfonamides

2019
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
    BMC nephrology, 2019, 02-04, Volume: 20, Issue:1

    Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia

2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:4

    Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult

2019
Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019, Volume: 19, Issue:9

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Graft Rejection; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Postoperative Period; Quinoxalines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Tissue and Organ Procurement; Treatment Outcome; Viral Load; Waiting Lists

2019
Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
    Clinical and translational gastroenterology, 2019, Volume: 10, Issue:4

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; RNA, Viral; Severity of Illness Index; Sulfonamides; Sustained Virologic Response

2019
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Journal of hepatology, 2019, Volume: 71, Issue:3

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Journal of hepatology, 2019, Volume: 71, Issue:4

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2019
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
    Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:12

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2020
Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.
    The Journal of antimicrobial chemotherapy, 2020, 07-01, Volume: 75, Issue:7

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Genotype; Hepacivirus; Hepatitis C, Chronic; Homosexuality, Male; Humans; Imidazoles; Male; Quality of Life; Quinoxalines; RNA, Viral; Sexual and Gender Minorities; Sulfonamides

2020
Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2020, Volume: 40, Issue:8

    Topics: Adult; Aged; Amides; Antiviral Agents; Asia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides

2020
Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection.
    The Journal of antimicrobial chemotherapy, 2020, 09-01, Volume: 75, Issue:9

    Topics: Adult; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides; Tablets

2020
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
    Clinical drug investigation, 2021, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Amides; Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Proteins; Pravastatin; Quinolines; Quinoxalines; Rosuvastatin Calcium; Sulfonamides; Young Adult

2021
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    The lancet. Gastroenterology & hepatology, 2022, Volume: 7, Issue:6

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure

2022
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
    Journal of viral hepatitis, 2022, Volume: 29, Issue:9

    Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides

2022

Other Studies

130 other study(ies) available for quinoxalines and carbamates

ArticleYear
[Toxicity by relay. II. A method for the asessment of safety to human consumers of carbadox, a growth-promoting additive to the feed of slaughter pigs].
    Toxicology, 1975, Volume: 3, Issue:3

    Topics: Animal Feed; Animals; Anti-Infective Agents; Body Weight; Carbamates; Diet; Dogs; Dose-Response Relationship, Drug; Estrus; Female; Fertility; Fetus; Food Additives; Growth Substances; Male; Meat; Methods; Potassium; Pregnancy; Quinoxalines; Rats; Reproduction; Sodium; Species Specificity; Swine; Time Factors

1975
Detection of naturally fluorescent pesticides on silica gel layers.
    Journal of chromatography, 1973, May-16, Volume: 79

    Topics: Benzimidazoles; Carbamates; Chromatography, Thin Layer; Coumarins; Dicarboxylic Acids; Dioxoles; Environmental Pollution; Fluorometry; Food Contamination; Fungicides, Industrial; Gels; Hot Temperature; Methods; Naphthalenes; Organothiophosphorus Compounds; Pesticide Synergists; Pesticides; Phenindione; Quinoxalines; Silicon Dioxide; Sulfides

1973
Spectrophotometric determination of carbadox in swine feeds.
    Journal - Association of Official Analytical Chemists, 1974, Volume: 57, Issue:4

    Topics: Animal Feed; Animals; Anti-Infective Agents; Carbamates; Chromatography; Food Additives; Quinoxalines; Solubility; Solvents; Spectrum Analysis; Swine

1974
Efficacy of carbadox in prevention of field outbreaks of swine dysentery.
    Veterinary medicine, small animal clinician : VM, SAC, 1973, Volume: 68, Issue:2

    Topics: Animals; Anti-Infective Agents; Carbamates; Disease Outbreaks; Dysentery; Quinoxalines; Swine; Swine Diseases

1973
Therapeutic efficacy of carbadox in field outbreaks of swine dysentery.
    Veterinary medicine, small animal clinician : VM, SAC, 1973, Volume: 68, Issue:3

    Topics: Animals; Anti-Infective Agents; Carbamates; Disease Outbreaks; Dysentery; Female; Male; Quinoxalines; Swine; Swine Diseases

1973
Carbadox: a new feed additive for pigs.
    Australian veterinary journal, 1972, Volume: 48, Issue:10

    Topics: Animals; Body Weight; Carbamates; Food Additives; Quinoxalines; Swine

1972
Quinoxaline precursors of fungitoxic benzimidazolycarbamates: syntheses and photochemically-induced transformations.
    Journal of the Chemical Society. Perkin transactions 1, 1973, Volume: 22

    Topics: Antifungal Agents; Benzimidazoles; Carbamates; Light; Methods; Mycotoxins; Oxides; Photochemistry; Quinoxalines; Radiation Effects

1973
Effect of carbadox in experimentally induced salmonellosis of swine.
    Journal of the American Veterinary Medical Association, 1974, Feb-15, Volume: 164, Issue:4

    Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Body Temperature; Body Weight; Carbamates; Colitis; Diarrhea; Female; Male; Quinoxalines; Salmonella; Salmonella Infections, Animal; Swine; Swine Diseases

1974
Evaluation of 5500 young pigs of Carbadox used at 50 ppm. Economic interpretation in reference with performances of control animals or supplements used at nutritional (less than or equal to 150 ppm) or therapeutic (greater than or equal to 200 ppm) levels
    Zeitschrift fur Tierphysiologie, Tierernahrung und Futtermittelkunde, 1974, Volume: 32, Issue:5

    Topics: Animal Feed; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Body Weight; Carbamates; Costs and Cost Analysis; Quinoxalines; Sulfamethazine; Swine

1974
Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor.
    Journal of medicinal chemistry, 1994, Mar-18, Volume: 37, Issue:6

    Topics: Animals; Carbamates; Cells, Cultured; GABA Antagonists; Imidazoles; Quinoxalines; Rats; Receptors, GABA; Stereoisomerism; Structure-Activity Relationship

1994
Presenilin attenuates receptor-mediated signaling and synaptic function.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2005, Feb-09, Volume: 25, Issue:6

    Topics: Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Carbamates; Carbazoles; Cell Adhesion Molecules; Cell Line, Tumor; Cell Membrane; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DCC Receptor; Dipeptides; Endopeptidases; Excitatory Postsynaptic Potentials; Genes, DCC; Glutamic Acid; Indoles; Lidocaine; Membrane Proteins; Memory; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurites; Neuroblastoma; Neurons; Piperazines; Presenilin-1; Protein Processing, Post-Translational; Pyrroles; Quinoxalines; Rats; Receptors, Cell Surface; Recombinant Fusion Proteins; Second Messenger Systems; Synaptic Transmission; Transfection; Tumor Suppressor Proteins

2005
Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling.
    Synapse (New York, N.Y.), 2009, Volume: 63, Issue:8

    Topics: Aniline Compounds; Animals; Animals, Newborn; Arachidonic Acids; Benzamides; Bicuculline; Biophysics; Calcium; Calcium Signaling; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Carbamates; Cerebellum; Electric Stimulation; Endocannabinoids; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Fluoresceins; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Glycerides; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Lactones; Mice; Muscimol; Orlistat; Patch-Clamp Techniques; Piperidines; Purkinje Cells; Pyrazoles; Quinoxalines; Rimonabant; Signal Transduction; Synapses; Valine

2009
Functional interactions of fibrillar and oligomeric amyloid-β with alpha7 nicotinic receptors in Alzheimer's disease.
    Journal of Alzheimer's disease : JAD, 2011, Volume: 23, Issue:2

    Topics: Aged; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Benzazepines; Carbamates; Cell Line, Tumor; Cells, Cultured; Frontal Lobe; Humans; Neurons; Nicotinic Agonists; PC12 Cells; Quinoxalines; Quinuclidines; Rats; Receptors, Nicotinic; Varenicline

2011
Multiresidue method for the determination of 13 pesticides in three environmental matrices: water, sediments and fish muscle.
    Talanta, 2011, Sep-15, Volume: 85, Issue:3

    Topics: Acetamides; Aminoimidazole Carboxamide; Animals; Benzimidazoles; Carbamates; Chemical Fractionation; Chromatography, Liquid; Environmental Monitoring; Fishes; Geologic Sediments; Hydantoins; Isoxazoles; Methacrylates; Muscles; Naphthalenes; Niacinamide; Oxazolidinones; Pesticide Residues; Pesticides; Phenylurea Compounds; Propionates; Pyrimidines; Quinoxalines; Reproducibility of Results; Solid Phase Extraction; Strobilurins; Sulfonylurea Compounds; Tandem Mass Spectrometry; Thiophenes; Water Pollutants, Chemical

2011
MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8

    Topics: Amides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Dogs; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Liver; Pan troglodytes; Protease Inhibitors; Quinoxalines; Rats; Sulfonamides; Viral Load; Viral Nonstructural Proteins

2012
Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Journal of chemical information and modeling, 2014, Feb-24, Volume: 54, Issue:2

    Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Molecular Dynamics Simulation; Mutation; Proline; Protease Inhibitors; Protein Conformation; Quinoxalines; Sulfonamides; Thermodynamics; Viral Nonstructural Proteins

2014
Development of a practical, asymmetric synthesis of the hepatitis C virus protease inhibitor MK-5172.
    Organic letters, 2013, Aug-16, Volume: 15, Issue:16

    Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Macrocyclic Compounds; Molecular Structure; Protease Inhibitors; Quinoxalines; Sulfonamides

2013
New kids on the block--step by step to an ideal HCV therapy.
    Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides

2015
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
    Journal of hepatology, 2015, Volume: 63, Issue:3

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Treatment Failure

2015
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2015, Volume: 123, Issue:10

    Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides

2015
Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:12

    Topics: Amides; Amino Acid Substitution; Antiviral Agents; Carbamates; Cell Line; Cyclopropanes; Drug Resistance, Viral; Genotype; Hepacivirus; Humans; Oligopeptides; Protease Inhibitors; Quinoxalines; Recombinant Proteins; Sulfonamides; Viral Nonstructural Proteins

2015
Structural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.
    ACS chemical biology, 2016, Apr-15, Volume: 11, Issue:4

    Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Quinoxalines; Sulfonamides; Thermodynamics; Viral Nonstructural Proteins

2016
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Imidazoles; Mutation; Protease Inhibitors; Quinoxalines; Replicon; Ribavirin; Sulfonamides

2016
The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:3

    Topics: Administration, Oral; Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Polymorphism, Genetic; Predictive Value of Tests; Quinoxalines; Sulfonamides; United States; Viral Nonstructural Proteins; Virology

2017
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:4

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Computer Simulation; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Quinoxalines; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; United States

2017
Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
    Canadian journal of gastroenterology & hepatology, 2017, Volume: 2017

    Topics: Amides; Antiviral Agents; Asthenia; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Randomized Controlled Trials as Topic; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Load

2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Gastroenterology, 2017, Volume: 152, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Randomized Controlled Trials as Topic; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult

2017
Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.
    The Journal of biological chemistry, 2017, 04-14, Volume: 292, Issue:15

    Topics: Amides; Amino Acid Substitution; Carbamates; Cell Line, Tumor; Cyclopropanes; Hepacivirus; Hepatitis C; Humans; Molecular Dynamics Simulation; Mutation, Missense; Quinoxalines; Simeprevir; Sulfonamides; Viral Nonstructural Proteins

2017
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
    European journal of clinical pharmacology, 2017, Volume: 73, Issue:5

    Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Contraceptives, Oral, Combined; Cyclopropanes; Drug Interactions; Ethinyl Estradiol; Female; Hepacivirus; Humans; Imidazoles; Levonorgestrel; Middle Aged; Quinoxalines; Sulfonamides; Young Adult

2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
    Contemporary clinical trials, 2017, Volume: 57

    Topics: Adult; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Macrocyclic Compounds; Male; Patient Participation; Patient-Centered Care; Prospective Studies; Pyrrolidines; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine

2017
Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
    Journal of viral hepatitis, 2017, Volume: 24, Issue:10

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Quinoxalines; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Failure; Treatment Outcome; Viral Load

2017
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut, 2018, Volume: 67, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Lipids; Male; Middle Aged; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate

2018
Preclinical and clinical properties of elbasvir (ERELSA
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2017, Volume: 150, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Evaluation, Preclinical; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides; Virus Activation

2017
Application of different spectrophotometric methods for simultaneous determination of elbasvir and grazoprevir in pharmaceutical preparation.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Jan-15, Volume: 189

    Topics: Algorithms; Amides; Benzofurans; Calibration; Carbamates; Cyclopropanes; Drug Compounding; Imidazoles; Least-Squares Analysis; Quinoxalines; Reference Standards; Regression Analysis; Reproducibility of Results; Spectrophotometry; Sulfonamides

2018
Brief Report: High Need to Switch cART or Comedication With the Initiation of DAAs in Elderly HIV/HCV-Coinfected Patients.
    Journal of acquired immune deficiency syndromes (1999), 2017, 10-01, Volume: 76, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Amides; Anti-Retroviral Agents; Antiviral Agents; Benzofurans; Carbamates; Coinfection; Combined Modality Therapy; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Imidazoles; Middle Aged; Quinoxalines; Retrospective Studies; Ritonavir; Sulfonamides; Young Adult

2017
Mavyret and Vosevi--two new combinations for chronic HCV infection.
    The Medical letter on drugs and therapeutics, 2017, 10-09, Volume: 59, Issue:1531

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome

2017
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
    Hepatology (Baltimore, Md.), 2018, Volume: 67, Issue:2

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins

2018
New Oral HCV Drug.
    The American journal of nursing, 2017, Volume: 117, Issue:11

    Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2017
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response

2018
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:2

    Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2018
Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
    Biochemistry, 2018, 02-06, Volume: 57, Issue:5

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins

2018
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.
    European journal of drug metabolism and pharmacokinetics, 2018, Volume: 43, Issue:3

    Topics: Adult; Aged; Amides; Benzofurans; Carbamates; Cyclopropanes; Female; Humans; Imidazoles; Liver Diseases; Male; Middle Aged; Quinoxalines; Sulfonamides

2018
New Drugs 2018, part 1.
    Nursing, 2018, Volume: 48, Issue:2

    Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration

2018
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides

2018
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
    Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides

2018
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
    Journal of gastroenterology, 2018, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Viral Load; Viral Nonstructural Proteins; Young Adult

2018
Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.
    PloS one, 2018, Volume: 13, Issue:3

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Liver Cirrhosis; Male; Middle Aged; Models, Economic; Quality-Adjusted Life Years; Quinoxalines; Randomized Controlled Trials as Topic; Renal Dialysis; RNA, Viral; Sulfonamides

2018
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:7

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2018
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Journal of gastroenterology, 2018, Volume: 53, Issue:12

    Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Japan; Male; Middle Aged; Multivariate Analysis; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response

2018
Simultaneous Determination of Elbasvir and Grazoprevir in Their Pharmaceutical Preparation Using High-Performance Liquid Chromatographic Method.
    Journal of chromatographic science, 2018, Sep-01, Volume: 56, Issue:8

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Combinations; Imidazoles; Limit of Detection; Models, Molecular; Pharmaceutical Preparations; Quinoxalines; Sulfonamides; Tablets

2018
Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
    Journal of viral hepatitis, 2018, Volume: 25, Issue:11

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; United States; Veterans

2018
Retreatment of hepatitis C virus: can it get any better?
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:8

    Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides

2018
Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube.
    Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Gastrostomy; Hepatitis C, Chronic; Humans; Imidazoles; Male; Quinoxalines; Sulfonamides

2018
Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be.
    Kidney international, 2018, Volume: 94, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Goals; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2018
Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease-Author's reply.
    Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:2

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Diseases; Quinoxalines; Retrospective Studies; Sulfonamides

2018
Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease.
    Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:2

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Diseases; Quinoxalines; Retrospective Studies; Sulfonamides

2018
Hepatitis C virus infection: 'beyond the liver'.
    BMJ case reports, 2018, Jul-25, Volume: 2018

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Dermatomyositis; Diagnosis, Differential; Female; Hepatitis C; Humans; Imidazoles; Quinoxalines; Sulfonamides; Viral Load

2018
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 02-01, Volume: 68, Issue:4

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2019
The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 02-01, Volume: 68, Issue:4

    Topics: Amides; Benzofurans; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Hepacivirus; HIV; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Quinoxalines; Ribavirin; Sexual and Gender Minorities; Sulfonamides

2019
Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.
    Structure (London, England : 1993), 2018, 10-02, Volume: 26, Issue:10

    Topics: Amides; Amino Acid Substitution; Antiviral Agents; Carbamates; Catalytic Domain; Crystallography, X-Ray; Cyclopropanes; Drug Resistance, Multiple, Viral; Hepacivirus; Humans; Models, Molecular; Molecular Dynamics Simulation; Mutation; Protease Inhibitors; Protein Conformation; Quinoxalines; Sulfonamides; Viral Nonstructural Proteins

2018
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:11

    Topics: Amides; Antiviral Agents; Carbamates; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Protease Inhibitors; Pyrrolidines; Quinoxalines; Replicon; Sulfonamides; Thiazoles; Uridine; Viral Nonstructural Proteins

2018
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
    Clinical drug investigation, 2018, Volume: 38, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sulfonamides; Valine

2018
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
    Antiviral research, 2018, Volume: 159

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Renal Insufficiency, Chronic; RNA, Viral; Sulfonamides; Sustained Virologic Response; Young Adult

2018
Synthesis of Grazoprevir, a Potent NS3/4a Protease Inhibitor for the Treatment of Hepatitis C Virus.
    Organic letters, 2018, 11-16, Volume: 20, Issue:22

    Topics: Amides; Antiviral Agents; Carbamates; Cyclization; Cyclopropanes; Hepacivirus; Molecular Structure; Quinoxalines; Serine Proteases; Sulfonamides; Viral Nonstructural Proteins

2018
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
    Internal medicine (Tokyo, Japan), 2019, Apr-01, Volume: 58, Issue:7

    Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine

2019
Management of acute HCV in the era of direct-acting antivirals: implications for elimination.
    The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:4

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2019
Hemoprotein-Catalyzed Cyclopropanation En Route to the Chiral Cyclopropanol Fragment of Grazoprevir.
    Chembiochem : a European journal of chemical biology, 2019, 05-02, Volume: 20, Issue:9

    Topics: Alkenes; Amides; Azo Compounds; Bacterial Proteins; Biocatalysis; Carbamates; Cyclization; Cyclopropanes; Directed Molecular Evolution; Hemeproteins; Molecular Structure; Mutagenesis, Site-Directed; Proof of Concept Study; Propanols; Quinoxalines; Sulfonamides; Verrucomicrobia

2019
Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5

    Topics: Adult; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Fluorenes; Humans; Imidazoles; Least-Squares Analysis; Male; Middle Aged; Pyridones; Quinoxalines; Sulfonamides; Triazoles

2019
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
    BMC infectious diseases, 2019, May-03, Volume: 19, Issue:1

    Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load

2019
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
    The American journal of gastroenterology, 2019, Volume: 114, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome

2019
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
    Journal of hepatology, 2019, Volume: 71, Issue:3

    Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult

2019
Possibilities and Limiting Factors for the Use of Dissolution as a Quality Control Tool to Detect Presence of Crystallinity for Amorphous Solid Dispersions: An Experimental and Modeling Investigation.
    Journal of pharmaceutical sciences, 2019, Volume: 108, Issue:9

    Topics: Amides; Carbamates; Chemistry, Pharmaceutical; Crystallization; Cyclopropanes; Drug Compounding; Drug Liberation; Feasibility Studies; Limit of Detection; Models, Chemical; Particle Size; Quality Control; Quinoxalines; Solubility; Sulfonamides; Tablets

2019
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
    Clinical and molecular hepatology, 2019, Volume: 25, Issue:4

    Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
    Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Discovery; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Structure; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Structure-Activity Relationship; Sulfonamides; Viral Nonstructural Proteins

2019
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom

2019
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
    PloS one, 2019, Volume: 14, Issue:8

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Mutation; Quinoxalines; Ribavirin; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins

2019
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV.
    Transplant infectious disease : an official journal of the Transplantation Society, 2019, Volume: 21, Issue:6

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Phosphoproteins; Pyrrolidines; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Viral Load; Viral Nonstructural Proteins

2019
Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
    Le infezioni in medicina, 2019, Sep-01, Volume: 27, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferon-alpha; Italy; Polypharmacy; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides

2019
Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:5

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Quinoxalines; Sulfonamides

2020
Simultaneous determination of elbasvir and grazoprevir in fixed-dose combination and mass spectral characterization of each degradation product by UHPLC-ESI-QTOF-MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2020, Jan-30, Volume: 178

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Combinations; Imidazoles; Quinoxalines; Sulfonamides; Tandem Mass Spectrometry

2020
Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Comorbidity; Cyclopropanes; Data Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Quinoxalines; Renal Insufficiency, Chronic; Retrospective Studies; Sex Factors; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult

2020
Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.
    Internal medicine (Tokyo, Japan), 2020, Apr-01, Volume: 59, Issue:7

    Topics: Adolescent; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine

2020
Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Antimicrobial agents and chemotherapy, 2020, 02-21, Volume: 64, Issue:3

    Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cell Line, Tumor; Culture Media; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Heterocyclic Compounds, 4 or More Rings; Humans; Microbial Sensitivity Tests; Mutation; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins

2020
Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With 99mTc-Mebrofenin Hepatobiliary Scintigraphy.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:2

    Topics: Adult; Amides; Aniline Compounds; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Interactions; Female; Glycine; Hepacivirus; Humans; Imidazoles; Imino Acids; Liver Failure; Organotechnetium Compounds; Quinoxalines; Radionuclide Imaging; Radiopharmaceuticals; Sulfonamides

2020
Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
    Antiviral research, 2020, Volume: 174

    Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Electronic Health Records; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonamides; United States; Veterans; Young Adult

2020
Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
    ACS chemical biology, 2020, 02-21, Volume: 15, Issue:2

    Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Catalytic Domain; Crystallography, X-Ray; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Mutation; Proline; Protein Binding; Quinoxalines; Serine Proteases; Serine Proteinase Inhibitors; Sulfonamides; Viral Nonstructural Proteins

2020
Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.
    Therapeutic drug monitoring, 2020, Volume: 42, Issue:2

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Drug Monitoring; Female; Half-Life; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets

2020
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:e1

    Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2020
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient.
    Renal failure, 2020, Volume: 42, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Middle Aged; Peritoneal Dialysis; Quinoxalines; Sulfonamides; Sustained Virologic Response

2020
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    European journal of gastroenterology & hepatology, 2021, 03-01, Volume: 33, Issue:3

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Registries; Sulfonamides; Sustained Virologic Response

2021
Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.
    The Journal of infectious diseases, 2020, 09-01, Volume: 222, Issue:7

    Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Duration of Therapy; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Quinoxalines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors

2020
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
    Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult

2020
Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
    The Korean journal of internal medicine, 2021, Volume: 36, Issue:Suppl 1

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Republic of Korea; Retrospective Studies; Sulfonamides

2021
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
    European journal of gastroenterology & hepatology, 2021, 06-01, Volume: 33, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2021
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan

2020
Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals.
    International journal of antimicrobial agents, 2020, Volume: 56, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Treatment Failure

2020
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
    Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2020, Volume: 84

    Topics: Amides; Amino Acid Sequence; Antiviral Agents; Betacoronavirus; Binding Sites; Caffeic Acids; Carbamates; Coronavirus Infections; Coumaric Acids; COVID-19; Cyclopropanes; Doxycycline; Gene Expression; Humans; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Nucleocapsid Proteins; Pandemics; Pneumonia, Viral; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Quinoxalines; Rutin; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Simeprevir; Sulfonamides; Thermodynamics; Viral Envelope Proteins; Viral Matrix Proteins; Virion

2020
Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
    Computers in biology and medicine, 2020, Volume: 122

    Topics: Amides; Betacoronavirus; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Dimerization; Drug Design; Drug Repositioning; Humans; Molecular Docking Simulation; Pandemics; Pneumonia, Viral; Protease Inhibitors; Quinoxalines; Rimantadine; SARS-CoV-2; Sulfonamides; Viral Proteins

2020
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
    Medicina clinica, 2021, 07-23, Volume: 157, Issue:2

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2021
Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
    Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:4

    Topics: Amides; Antiviral Agents; Benzofurans; Biomarkers; Carbamates; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Quinoxalines; Sulfonamides; Valine

2021
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 11-02, Volume: 73, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2021
Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
    Antiviral therapy, 2020, Volume: 25, Issue:6

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Quinoxalines; Sulfonamides

2020
Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients.
    Medicine, 2020, Sep-11, Volume: 99, Issue:37

    Topics: Adult; Alanine Transaminase; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2020
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
    Zeitschrift fur Gastroenterologie, 2020, Volume: 58, Issue:9

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2020
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    European journal of gastroenterology & hepatology, 2022, 01-01, Volume: 34, Issue:1

    Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response

2022
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4

    Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Quinoxalines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Taiwan; Treatment Outcome; Valine

2021
Simultaneous determination of elbasvir and grazoprevir in their pharmaceutical formulation by synchronous fluorescence spectroscopy coupled to dual wavelength method.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2021, Mar-05, Volume: 248

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Compounding; Imidazoles; Quinoxalines; Spectrometry, Fluorescence; Sulfonamides; Tablets

2021
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
    Medicine, 2020, Nov-25, Volume: 99, Issue:48

    Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load

2020
Simultaneous spectrophotometric quantitative analysis of elbasvir and grazoprevir using assisted chemometric models.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2021, May-05, Volume: 252

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Imidazoles; Quinoxalines; Spectrophotometry; Sulfonamides

2021
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.
    Expert review of gastroenterology & hepatology, 2021, Volume: 15, Issue:9

    Topics: Adult; Age Distribution; Aged; Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response

2021
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 06-01, Volume: 72, Issue:11

    Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides

2021
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:9

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins

2021
Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.
    Journal of viral hepatitis, 2021, Volume: 28, Issue:6

    Topics: Amides; Analgesics, Opioid; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Pharmaceutical Preparations; Prospective Studies; Quinoxalines; Sulfonamides

2021
Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir.
    Scientific reports, 2021, 03-31, Volume: 11, Issue:1

    Topics: Amides; Angiotensin-Converting Enzyme 2; Antiviral Agents; Carbamates; Coronavirus RNA-Dependent RNA Polymerase; Cyclopropanes; Drug Repositioning; Humans; Models, Molecular; Molecular Dynamics Simulation; Quinoxalines; Serine Endopeptidases; Sulfonamides; Virus Internalization

2021
Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PloS one, 2021, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Young Adult

2021
The numerical probability of carcinogenicity to humans of some antimicrobials: Nitro-monoaromatics (including 5-nitrofurans and 5-nitroimidazoles), quinoxaline-1,4-dioxides (including carbadox), and chloramphenicol.
    Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 75

    Topics: Animals; Anti-Infective Agents; Biological Assay; Carbamates; Carcinogens; Humans; Nitro Compounds; Predictive Value of Tests; Probability; Quinoxalines; Risk Assessment

2021
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
    Scientific reports, 2021, 05-13, Volume: 11, Issue:1

    Topics: Amides; Antiviral Agents; Carbamates; COVID-19 Drug Treatment; Cyclopropanes; Drug Repositioning; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Domains; Quinoxalines; RNA Helicases; SARS-CoV-2; Sulfonamides; Triazoles; Viral Proteins

2021
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
    Internal medicine (Tokyo, Japan), 2021, Nov-01, Volume: 60, Issue:21

    Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome

2021
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
    Biochemical and biophysical research communications, 2021, 09-24, Volume: 571

    Topics: Amides; Antiviral Agents; Benzimidazoles; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Drug Evaluation, Preclinical; Drug Repositioning; Fluorenes; Humans; Lactams, Macrocyclic; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Proline; Protein Conformation; Quinoxalines; SARS-CoV-2; Sulfonamides

2021
Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Annals of surgery, 2021, 10-01, Volume: 274, Issue:4

    Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Quinoxalines; Retrospective Studies; Sofosbuvir; Sulfonamides; Sustained Virologic Response

2021
Successful treatment of chronic hepatitis C virus infection with crushed elbasvir/grazoprevir administered through a nasogastric tube in a patient with hypoxic encephalopathy.
    The Kaohsiung journal of medical sciences, 2022, Volume: 38, Issue:1

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypoxia, Brain; Imidazoles; Intubation, Gastrointestinal; Middle Aged; Quinoxalines; Sulfonamides

2022
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:12

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides

2021
Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2022, Volume: 54, Issue:8

    Topics: Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; RNA; Sulfonamides

2022
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
    Zeitschrift fur Gastroenterologie, 2022, Volume: 60, Issue:6

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome

2022
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection.
    Antimicrobial agents and chemotherapy, 2022, 02-15, Volume: 66, Issue:2

    Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Middle Aged; Quinoxalines; Sulfonamides

2022
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
    Hepatology (Baltimore, Md.), 2022, Volume: 76, Issue:2

    Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome

2022
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:11

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome

2022
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
    Journal of gastroenterology and hepatology, 2022, Volume: 37, Issue:8

    Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome

2022
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    Journal of hepatology, 2022, Volume: 77, Issue:4

    Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides

2022
Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder.
    The American journal of drug and alcohol abuse, 2022, 07-04, Volume: 48, Issue:4

    Topics: Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Opioid-Related Disorders; Quinoxalines; Sulfonamides

2022